Page 87 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Pain Physician: August 2020 COVID-19 Special Issue 23:S391-S420

Improvement in LV end-systolic volume index, wall motion index, B-type natriuretic peptide, and 6-minute walking distance. MSC infused during CABG. Decrease in E/e ratio and left Increase in global EF, infarct wall movement velocity SVI, and NYHA classification. Decrease of infarct size and LVESV (3 and 12 months). MSC infusion 28 Improvement in ischemic myocardium, systolic LV function in patients with low ejection at baseline in patients

Findings atrial volume. months after MI. coronary sinus. and infarct size. defect. microobstruction.

Follow- Up 6 12 12 24 6 6 144 6

LVEF Impact Yes - improvement Not assessed Yes Yes - improvement No No Yes – improvement Yes - improvement

Outcome Yes Yes Yes Yes No Yes Yes Yes

Condition IHD HF IHD IHD IHD IHD IHD IHD

Delivery Method CABG IC IC IC IC IC IC IC

Type of Stem Cell BM MNC BM MNC BMC BM MNC BM MNC Adipose SVF BM MNC BM MNC

Number of SCs 100 million 647 + 889 million Not disclosed 800 million 800 million 17 million UNK 324 million

Table 2 con't. MSC therapy studies treating cardiac failure.
BMA (mL) 60 150 120 300 300 200 UNK 15

No. of Patients in Treatment Group 31 32 38 14 15 10 40 29

Type of Study RCT Case series RCT Case series RCT RCT RCT RCT

Year 2011 2011 2011 2011 2011 2012 2011 2013

Author Hu et al, J Am Coll Cardiol 2011; 57:2409-2415 Diederichsen et al, Scand Cardiovasc J 2010; 44:139-145 Turan et al, Stem Cell Rev Rep 2011; 7:646-656 Tuma et al, J Transl Med 2011; 9:183 Hopp et al, J Transl Med 2011; 13:22 Houtgraaf et al, J Am Coll Cardiol 2012; 59:539-540 Plewka et al, J Am Coll Cardiol 2011; 69:1234-1240 Wohrle et al, Clin Res Cardiol 2013; 102:765-770

S404 www.painphysicianjournal.com